Donor-Derived Myeloid Heme Oxygenase-1 Controls the Development of Graft-Versus-Host Disease.

Chloé Spilleboudt,Florence Beckerich,Virginie De Wilde,Miguel P Soares,Judith Racapé,Marc Abramowicz,Ludovic Cabanne,Véronique Flamand,Jean-Michel Hougardy,Benoît Vokaer,Alain Le Moine,Philippe Lewalle,Mathieu Leclerc,Dominique Bories,Sébastien Maury,Silvia Cardoso

doi:10.3389/fimmu.2020.579151

Abstract

Graft-versus-host disease (GVHD) remains a major clinical drawback of allogeneic hematopoietic stem cell transplantation (HSCT). Here, we investigated how the stress responsive heme catabolizing enzyme heme oxygenase-1 (HO-1, encoded by HMOX1) regulates GVHD in response to allogeneic hematopoietic stem cell transplantation in mice and humans. We found that deletion of the Hmox1 allele, specifically in the myeloid compartment of mouse donor bone marrow, promotes the development of aggressive GVHD after allogeneic transplantation. The mechanism driving GVHD in mice transplanted with allogeneic bone marrow lacking HO-1 expression in the myeloid compartment involves enhanced T cell alloreactivity. The clinical relevance of these observations was validated in two independent cohorts of HSCT patients. Individuals transplanted with hematopoietic stem cells from donors carrying a long homozygous (GT)n repeat polymorphism (L/L) in the HMOX1 promoter, which is associated with lower HO-1 expression, were at higher risk of developing severe acute GVHD as compared to donors carrying a short (GT)n repeat (S/L or S/S) polymorphism associated with higher HO-1 expression. In this study, we showed the unique importance of donor-derived myeloid HO-1 in the prevention of lethal experimental GVHD and we corroborated this observation by demonstrating the association between human HMOX1 (GT)n microsatellite polymorphisms and the incidence of severe acute GVHD in two independent HSCT patient cohorts. Donor-derived myeloid HO-1 constitutes a potential therapeutic target for HSCT patients and large-scale prospective studies in HSCT patients are necessary to validate the HO-1 L/L genotype as an independent risk factor for developing severe acute GVHD.

Highlights

Acute graft-versus-host disease (GVHD) remains a major cause of mortality after allogeneic hematopoietic stem cell transplantation (HSCT) [1, 2]
We showed the unique importance of donor-derived myeloid heme oxygenase-1 (HO-1) in the prevention of lethal experimental GVHD and we corroborated this observation by demonstrating the association between human HMOX1 (GT)n microsatellite polymorphisms and the incidence of severe acute GVHD in two independent HSCT patient cohorts
Survival of C57BL/6 recipients transplanted with allogeneic bone marrow (BM) and spleen cells from BALB/c mice was compromised when the donor cells lacked HO-1 expression (BALB/c Hmox1−/− donors), as compared to C57BL/6 recipients transplanted with donor cells expressing HO-1 (BALB/c Hmox1+/+ donors) (Figure 1B)

Summary

Introduction

Acute graft-versus-host disease (GVHD) remains a major cause of mortality after allogeneic HSCT [1, 2]. This pathologic process is counter-regulated by regulatory T cells (TREGS) [3, 4] as well as by myeloid-derived suppressor cells (MDSCs) [5, 6]. Heme catabolism by HO-1 counter-regulates the rejection of transplanted cells, tissues, or organs in a variety of experimental conditions [16] In keeping with this notion, we have previously shown that MDSCs block T cell-mediated allograft rejection via a mechanism that is dependent on the expression of HO-1 [17]. Whether natural endogenous levels of HO-1 limit GVHD and its sources, and the contribution of donor versus recipient HO-1 remain critical open questions

Methods

Results

Conclusion